Laura J Bierut

Alumni Endowed Professor

Washington University in Saint Louis School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Laura J. Bierut is the Alumni Endowed Professor at Washington University in Saint Louis School of Medicine, USA. Her research primarily focuses on the intersection of genetics and brain health, with recent articles examining topics such as hippocampal volumes in relation to APOE in older adults, smoking behavior's impact on global brain volume, and genome-wide DNA methylation differences in smokers and nonsmokers. She also investigates methods for data collection in research, particularly concerning smoking cessation and biomarkers.

Articles (12)

INTRODUCTION The hippocampus atrophies with age and is implicated in neurodegenerative disorders including Alzheimer's disease (AD). We examined the interplay between age and apolipoprotein E ( APOE ) genotype on total hippocampal volume. METHODS Using neuroimaging data from 37,463 UK Biobank participants, we applied linear regression to quantify the association of age and APOE with hippocampal volume and identified the age when volumes of ε2/ε3, ε3/ε4, and ε4/ε4 carriers significantly deviated from ε3/ε3 using generalized additive modeling. RESULTS Total hippocampal volume declined with age, with significant differences by APOE genotype emerging after age 60. ε3/ε4 and ε4/ε4 carriers displayed reduced volumes from ages 69 and 61, respectively, while ε2/ε3 showed delayed decline starting at the age of 76. DISCUSSION The association of APOE and hippocampal volume is age‐dependent, with differences in volumes of ε4/ε4 carriers detected as early as age 61. This work underscores the importance of APOE genotype in determining when to begin screening for AD. Highlights Apolipoprotein E ( APOE ) genotype shows an age‐dependent association with total hippocampal volume. No association between APOE and total hippocampal volume was detected before age 60. Accelerated decline was observed in ε4/ε4 carriers at age 61 and ε3/ε4 at age 69. Delayed decline was evident in ε2/ε3 carriers starting at age 76.

Year:

2024

Year:

2024

Alcohol use and smoking are common substance-use behaviors with well-established negative health effects, including decreased brain health. We examined whether alcohol use and smoking were associated with the same neuroimaging-derived brain measures. We further explored whether the effects of alcohol use and smoking on the brain were additive or interactive. We leveraged a cohort of 36,309 participants with neuroimaging data from the UK Biobank. We used linear regression to determine the association between 354 neuroimaging-derived brain measures and alcohol use defined as drinks per week, pack years of smoking, and drinks per week x pack years smoking interaction. To assess whether the brain associations with alcohol are broadly similar or different from the associations with smoking, we calculated the correlation between z-scores of association for drinks per week and pack years smoking. Results indicated overall moderate positive correlation in the associations across measures representing brain structure, magnetic susceptibility, and white matter tract microstructure, indicating greater similarity than difference in the brain measures associated with alcohol use and smoking. The only evidence of an interaction between drinks per week and pack years smoking was seen in measures representing magnetic susceptibility in subcortical structures. The effects of alcohol use and smoking on brain health appeared to be additive rather than multiplicative for all other brain measures studied. 97% (224/230) of associations with alcohol and 100% (167/167) of the associations with smoking that surpassed a p value threshold are in a direction that can be interpreted to reflect reduced brain health. Our results underscore the similarity of the adverse associations between use of these substances and neuroimaging derived brain measures.

Year:

2024

INTRODUCTION The hippocampus atrophies with age and is implicated in neurodegenerative disorders including Alzheimer’s disease (AD). We examined the interplay between age and APOE genotype on total hippocampal volume. METHODS Utilizing neuroimaging data from 37,463 UK Biobank participants, we applied linear regression to quantify the association of age and APOE with hippocampal volume and identified the age when volumes of ε2/ε3, ε3/ε4, and ε4/ε4 carriers significantly deviated from ε3/ε3 using generalized additive modeling. RESULTS Total hippocampal volume declined with age, with significant differences by APOE genotype emerging after age 60. ε3/ε4 and ε4/ε4 carriers displayed reduced volumes from ages 69 and 61, respectively, while ε2/ε3 showed delayed decline starting at age 76. DISCUSSION The association of APOE and hippocampal volume is age-dependent, with differences in volumes of ε4/ε4 carriers detected as early as age 61. This work underscores the importance of APOE genotype in determining when to begin screening for AD.

Year:

2024

Excessive alcohol consumption is a leading cause of preventable death worldwide. Neurobiological mechanisms associated with alcohol use disorder (AUD) remain poorly understood. To further understand differential gene expression (DGE) associated with AUD, we compared deceased individuals with and without AUD across two human brain regions, nucleus accumbens (NAc) and dorsolateral prefrontal cortex (DLPFC). Bulk RNA-seq data in both NAc and DLPFC from human postmortem brains (N ≥ 50 with AUD and ≥ 46 non-AUD) were analyzed for DGE using negative binomial regression adjusting for technical and biological covariates. The region-level results were meta-analyzed with a previously published, independent dataset (N NAc = 28 AUD, 29 non-AUD; N PFC = 66 AUD, 77 non-AUD). We further utilized these data to test for heritability enrichment of AUD-related phenotypes, gene co-expression networks, gene ontology enrichment, and drug repurposing. We identified 176 differentially expressed genes (DEGs; 12 in both regions, 78 only in NAc, 86 only in DLPFC) for AUD in our new dataset. By meta-analyzing with published data, we identified 476 DEGs (25 in both regions, 29 only in NAc, 422 only in PFC). Of these DEGs, we found 17 genes that were significant when looked up in GWAS of problematic alcohol use or drinks per week. Gene co-expression analysis showed both concordant and unique gene networks across brain regions. We also identified 29 and 436 drug compounds that target DEGs from our meta-analysis in NAc and DLPFC, respectively. This study identified robust AUD-associated DEGs, providing novel neurobiological insights into AUD and highlighting genes targeted by known drug compounds, generating opportunity for drug repurposing to treat AUD.

Year:

2024

Background Alcohol use disorder (AUD) has a profound public health impact. However, understanding of the molecular mechanisms underlying the development and progression of AUD remain limited. Here, we interrogate AUD-associated DNA methylation (DNAm) changes within and across addiction-relevant brain regions: the nucleus accumbens (NAc) and dorsolateral prefrontal cortex (DLPFC). Methods Illumina HumanMethylation EPIC array data from 119 decedents of European ancestry (61 cases, 58 controls) were analyzed using robust linear regression, with adjustment for technical and biological variables. Associations were characterized using integrative analyses of public gene regulatory data and published genetic and epigenetic studies. We additionally tested for brain region-shared and -specific associations using mixed effects modeling and assessed implications of these results using public gene expression data. Results At a false discovery rate ≤ 0.05, we identified 53 CpGs significantly associated with AUD status for NAc and 31 CpGs for DLPFC. In a meta-analysis across the regions, we identified an additional 21 CpGs associated with AUD, for a total of 105 unique AUD-associated CpGs (120 genes). AUD-associated CpGs were enriched in histone marks that tag active promoters and our strongest signals were specific to a single brain region. Of the 120 genes, 23 overlapped with previous genetic associations for substance use behaviors; all others represent novel associations. Conclusions Our findings identify AUD-associated methylation signals, the majority of which are specific within NAc or DLPFC. Some signals may constitute predisposing genetic and epigenetic variation, though more work is needed to further disentangle the neurobiological gene regulatory differences associated with AUD.

Year:

2024

Combination antiretroviral therapy (ART) has changed the landscape of the HIV epidemic by providing an effective means for viral suppression to people living with HIV (PLWH). Understanding living with HIV as a chronic disease requires an improved understanding of how HIV and/or ART impacts susceptibility to and development of co-occurring conditions. Genome-wide gene expression (transcriptome) differences provide a key view into biological dysregulation associated with living with HIV. Here we present the first whole blood transcriptome-wide study comparing gene expression profiles between virally suppressed PLWH and HIV negative individuals (N=555). We identify 566 genes and 5 immune cell types with differential proportions by HIV status, which were significantly enriched for immune function and cancer pathways. Leveraging quantitative trait loci (QTL) for these HIV status-associated genes, partitioned heritability, and colocalization analyses, we observed limited genetic drivers of these relationships. Our findings suggest that gene dysregulation does not return to a pre-infection state for virally suppressed PLWH, and that persistent gene dysregulation is broadly associated with immune function and cancer pathways, highlighting potential biological drivers for these causes of excess mortality and targets for pharmacological preventative treatment among PLWH.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2020

Collaborators (12)

Kanna Hayashi

St. Paul's Hospital Chair in Substance Use Research and Associate Professor

Simon Fraser University

CANADA
View details

Michaël Belloy

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Janine Bijsterbosch

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Randi Foraker

Professor and Chair

University of Missouri System

UNITED STATES
View details

Kora DeBeck

Associate Professor

Simon Fraser University - Vancouver

CANADA
View details

Brian Gordon

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Andrey Anokhin

Professor of Psychiatry

Washington University School of Medicine

UNITED STATES
View details

Shizhong Han

Lead Investigator

Johns Hopkins University School of Medicine

UNITED STATES
View details

Bradley Webb

Assistant Professor

Virginia Commonwealth University

UNITED STATES
View details

Shaunna Clark

Associate Professor

Texas A&M University

UNITED STATES
View details

Sarah Hartz

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Lea Zillich

University Medical Center Freiburg

GERMANY
View details